Envista Holdings Co. (NYSE:NVST) Given Consensus Rating of “Hold” by Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have been given a consensus recommendation of “Hold” by the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $20.71.

A number of analysts have recently issued reports on the company. Wells Fargo & Company assumed coverage on Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 target price on the stock. Robert W. Baird lifted their target price on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. lowered Envista from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $23.00 to $16.00 in a report on Thursday, August 8th. Evercore ISI boosted their price objective on Envista from $18.00 to $23.00 and gave the company an “outperform” rating in a report on Monday, September 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, October 31st.

Envista Trading Down 1.3 %

NYSE:NVST opened at $20.08 on Friday. The business’s 50-day moving average is $19.09 and its two-hundred day moving average is $18.12. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. Envista has a 12 month low of $15.15 and a 12 month high of $25.64. The firm has a market capitalization of $3.46 billion, a PE ratio of -2.58, a price-to-earnings-growth ratio of 2.86 and a beta of 1.30.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same period last year, the company posted $0.43 earnings per share. The firm’s revenue was down 4.8% compared to the same quarter last year. Research analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Several hedge funds and other institutional investors have recently made changes to their positions in the business. William Blair Investment Management LLC boosted its position in shares of Envista by 4.0% during the first quarter. William Blair Investment Management LLC now owns 14,049 shares of the company’s stock worth $300,000 after buying an additional 538 shares during the period. GAMMA Investing LLC boosted its position in shares of Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the period. Victory Capital Management Inc. boosted its position in shares of Envista by 2.3% during the second quarter. Victory Capital Management Inc. now owns 36,021 shares of the company’s stock worth $599,000 after buying an additional 800 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.